Extracellular ATP promotes cancer cell drug resistance to tyrosine kinase inhibitors by competing for the ATP-binding site of tyrosine kinase

被引：0
|
作者：
Wang, Xuan [1 ]
Qian, Yanrong [1 ]
Li, Yunsheng [1 ]
Chen, Xiaozhuo [1 ]
机构：
[1] Ohio Univ, Athens, OH 45701 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-5462
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5462
引用
收藏
页数：1
相关论文
共 50 条
  • [31] In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile
    Han, Ho-Jae
    Kim, Jaeyoon John
    Pyne, Danielle
    Travas, Anthea
    Ambalavanan, Amirthagowri
    Kimura, Shinya
    Deininger, Michael W.
    Kim, Jong-Won
    Kim, Dennis Dong Hwan
    LEUKEMIA, 2024, 38 (02) : 412 - 415
  • [32] In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile
    Ho-Jae Han
    Jaeyoon John Kim
    Danielle Pyne
    Anthea Travas
    Amirthagowri Ambalavanan
    Shinya Kimura
    Michael W. Deininger
    Jong-Won Kim
    Dennis Dong Hwan Kim
    Leukemia, 2024, 38 : 412 - 415
  • [33] ANTIBODIES TO THE ATP-BINDING SITE OF THE HUMAN EPIDERMAL GROWTH-FACTOR (EGF) RECEPTOR AS SPECIFIC INHIBITORS OF EGF-STIMULATED PROTEIN-TYROSINE KINASE-ACTIVITY
    GULLICK, WJ
    DOWNWARD, J
    FOULKES, JG
    WATERFIELD, MD
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 158 (02): : 245 - 253
  • [34] Rational modification of semaxanib and sunitinib for developing a tumor growth inhibitor targeting ATP binding site of tyrosine kinase
    Kaur, Jagroop
    Kaur, Baljit
    Singh, Palwinder
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (02) : 129 - 133
  • [35] Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
    Kuwano, Michihiko
    Sonoda, Kahori
    Murakami, Yuichi
    Watari, Kosuke
    Ono, Mayumi
    PHARMACOLOGY & THERAPEUTICS, 2016, 161 : 97 - 110
  • [36] Tyrosine kinase inhibitors in cancer therapy
    Madhusudan, S
    Ganesan, TS
    CLINICAL BIOCHEMISTRY, 2004, 37 (07) : 618 - 635
  • [37] Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
    Hamdi, Amir Imran Faisal
    How, Soon Hin
    Islam, Mohammad Kaisarul
    Lim, Jonathan Chee Woei
    Stanslas, Johnson
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (12) : 1309 - 1323
  • [38] Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer
    Tong, Christy W. S.
    Wu, William K. K.
    Loong, Herbert H. F.
    Cho, William C. S.
    To, Kenneth K. W.
    CANCER LETTERS, 2017, 405 : 100 - 110
  • [39] Cancer exosomes as a new mediator to spread drug resistance to EGFR tyrosine kinase inhibitors
    To, Kenneth K. W.
    Tong, Christy W. S.
    Wu, Mia M. X.
    CANCER RESEARCH, 2018, 78 (13)
  • [40] Tyrosine kinase inhibitors as cancer therapy
    Nichols, GL
    CANCER INVESTIGATION, 2003, 21 (05) : 758 - 771
12345